Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) hit a new 52-week high on Friday . The stock traded as high as $104.00 and last traded at $102.8650, with a volume of 268369 shares traded. The stock had previously closed at $102.82.
Analysts Set New Price Targets
Several equities research analysts have weighed in on the company. Citigroup reissued an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Mizuho boosted their price objective on Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 27th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $101.86.
Get Our Latest Research Report on Lantheus
Lantheus Stock Performance
Lantheus (NASDAQ:LNTH – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter in the prior year, the firm earned $1.53 earnings per share. Lantheus’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.42 EPS for the current fiscal year.
Institutional Trading of Lantheus
Hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new stake in Lantheus during the third quarter worth $1,847,000. American Assets Inc. purchased a new stake in Lantheus during the third quarter worth $872,000. Assetmark Inc. lifted its holdings in Lantheus by 20.1% during the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock worth $6,078,000 after buying an additional 19,844 shares during the period. Vanguard Group Inc. lifted its holdings in Lantheus by 1.7% during the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after buying an additional 115,338 shares during the period. Finally, Heron Bay Capital Management purchased a new stake in Lantheus during the third quarter worth $861,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.
The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.
Featured Articles
- Five stocks we like better than Lantheus
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
